<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        9-5603-21
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2010
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        CEPROTIN 500 IU POWDER FOR SOLUTION FOR INJECTION OR INFUSION
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        PROTEIN C
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        500
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        IU
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Powder for solution for injection/infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        3782.30
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="TAKEDA MANUFACTURING AUSTRIA AG" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            TAKEDA MANUFACTURING AUSTRIA AG
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 583]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            ALNAGHI COMPANY
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Takeda Manufacturing AG
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        B01AD12
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>1. WHAT CEPROTIN IS AND WHAT IT IS USED FOR<br />CEPROTIN belongs to a class of medicines called<br />antithrombotics. This medicine contains Protein C, a<br />natural protein that is made in the liver and is<br />present in your blood. Protein C plays a major role in<br />prevention of excessive clot formation thus, prevent<br />and/or treat intravascular thrombosis.<br />CEPROTIN is used in the treatment and prevention<br />of thrombotic and haemorrhagic skin lesions (named<br />purpura fulminans) in patients with severe congenital<br />protein C deficiency. Additionally, CEPROTIN may be<br />used to treat a rare complication of a blood thinner<br />medication (anticoagulant medication named<br />coumarin) which may result in severe skin lesion<br />(necrosis).<br />Furthermore CEPROTIN is used to prevent<br />thrombosis in patients with severe congenital protein<br />C deficiency if one or more of the following<br />conditions are met:<br />&bull; surgery or invasive therapy is imminent<br />&bull; while initiating coumarin (anticoagulant<br />medication, blood thinner) therapy<br />&bull; when coumarin therapy alone is not sufficient<br />&bull; when coumarin therapy is not feasible.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not use CEPROTIN<br />&ndash; if you are allergic to Human Protein C or any of<br />the other ingredients of this medicine (listed in<br />section 6) including mouse protein or heparin.<br />However, in the case of life-threatening thrombotic<br />complications your doctor may still decide to<br />continue treatment with CEPROTIN.<br />Warnings and precautions<br />Talk to your doctor or pharmacist before using<br />CEPROTIN. Take special care with CEPROTIN if<br />symptoms of allergy occur. Symptoms of allergy<br />include rash, hives, breathing difficulties, low blood<br />pressure, tightness of chest, and shock. If such<br />symptoms occur during the administration of<br />CEPROTIN, injection should be stopped. Such<br />symptoms may constitute an allergic reaction to any<br />of the components, to mouse protein or heparin. Thepreparation may contain traces of heparin and/or<br />mouse protein as a result of the manufacturing<br />process. If such a reaction occurs, your doctor will<br />decide on the most appropriate treatment.<br />If the preparation is used in patients with severe<br />congenital protein C deficiency, antibodies inhibiting<br />protein C may develop that can inhibit protein C and<br />therefore diminish the effect of the preparation.<br />However, this has not been observed in the clinical<br />studies to date.<br />When medicines are made from human blood or<br />plasma, certain measures are put in place to prevent<br />infections being passed on to patients. These include<br />careful selection of blood and plasma donors to<br />make sure those at risk of carrying infections are<br />excluded, and the testing of each donation and pools<br />of plasma for signs of virus/infections. Manufacturers<br />of these products also include steps in the<br />processing of the blood or plasma that can inactivate<br />or remove viruses. Despite these measures, when<br />medicines prepared from human blood or plasma are<br />administered, the possibility of passing on infection<br />cannot be totally excluded. This also applies to any<br />unknown or emerging viruses or other types of<br />infections.<br />The measures taken are considered effective for<br />enveloped viruses such as human immunodeficiency<br />virus (HIV), hepatitis B virus and hepatitis C virus,<br />and for the non-enveloped hepatitis A virus. The<br />measures taken may be of limited value against nonenveloped<br />viruses such as parvovirus B19.<br />Parvovirus B 19 infection may be serious for<br />pregnant women (fetal infection) and for individuals<br />whose immune system is depressed or who have<br />some types of anaemia (e.g. sickle cell disease or<br />haemolytic anaemia).<br />Your doctor may recommend that you consider<br />vaccination against hepatitis A and B if you regularly/<br />repeatedly receive human plasma-derived Protein C<br />products.<br />Other medicines and CEPROTIN<br />No interactions with other medicinal products are<br />currently known.<br />Nevertheless, please tell your doctor or pharmacist if<br />you are taking or have recently taken any other<br />medicines, including medicines obtained without a<br />prescription.<br />If you change to treatment with oral anticoagulants,<br />treatment with CEPROTIN must continue until the<br />blood level of the oral anticoagulation is adequate<br />and stable.<br />CEPROTIN with food and drink<br />Not applicable.<br />Pregnancy and breast-feeding<br />If you are pregnant or breast-feeding, think you may<br />be pregnant or are planning to have a baby, ask your<br />doctor or pharmacist for advice before taking this<br />medicine.<br />Your doctor will decide if CEPROTIN may be used<br />during pregnancy and lactation.<br />Driving and using machines<br />CEPROTIN has no influence on your ability to drive<br />or to operate machines.<br />Important information about some of the ingredients<br />of CEPROTIN<br />As the quantity of sodium in the maximum daily dose<br />may exceed 200 mg, this should be taken into<br />consideration by patients on a controlled sodium<br />diet.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>CEPROTIN is intended for intravenous administration<br />(infusion into a vein). It is given to you under close<br />supervision of your doctor who is experienced in<br />substitution therapy of coagulation factors/inhibitors<br />and where monitoring of protein C activity is<br />possible. Dosage will vary depending on your<br />condition and your body weight.<br />Dosage<br />The dose, administration frequency and duration of<br />treatment depend on the severity of the protein C<br />deficiency as well as on your clinical condition and<br />on your plasma level of protein C. They should be<br />adjusted accordingly on the basis of clinical<br />effectiveness and laboratory assessment.<br />A protein C activity of 100 % should be achieved<br />initially and the activity should be maintained above<br />25 % for the duration of the treatment.<br />An initial dose of 60 to 80 IU/kg should be<br />administered. Your physician will take several blood<br />drawings over time to determine how long protein C<br />is remaining in your body.<br />The measurement of protein C activity using<br />chromogenic substrates is recommended for the<br />determination of your plasma level for protein C<br />before and during treatment with CEPROTIN.<br />The dosage should be determined on the basis of<br />laboratory measurements of the protein C activity. In<br />the case of an acute thrombotic event these should be<br />performed every 6 hours until your condition is<br />stabilised, thereafter twice a day and always<br />immediately before the next injection. It should be kept<br />in mind that the half-life of protein C may be severely<br />shortened in certain clinical conditions such as acute<br />thrombosis with purpura fulminans and skin necrosis.<br />If you have kidney and/or liver disease, please inform<br />your doctor, because he may have to adjust your<br />treatment accordingly.<br />If you are switched to permanent prophylaxis with<br />oral anticoagulants, protein C replacement is to be<br />discontinued only when stable anticoagulation is<br />obtained (see &ldquo;Important information about some of<br />the ingredients of CEPROTIN&rdquo;).<br />If you receive prophylactic administration of protein<br />C, higher trough levels may be warranted in<br />situations of an increased risk of thrombosis (such<br />as infection, trauma, or surgical intervention).<br />If you have APC resistance which is a<br />thromboembolic risk factor present in up to 5 % of<br />the population in Europe your doctor may need to<br />adjust your treatment accordingly.<br />Administration<br />CEPROTIN will be administered to you by<br />intravenous injection after reconstitution of the<br />powder for solution for injection with Sterilised Water<br />for Injections. It is strongly recommended that every<br />time you receive a dose of CEPROTIN the name and<br />batch number of the product are recorded in order to<br />maintain a record of the batches used.<br />Reconstitute lyophilised CEPROTIN powder for<br />solution for injection, with the supplied solvent<br />(Sterilised Water for Injections) using the sterile<br />transfer needle. Gently rotate the vial until all powder<br />is dissolved.<br />After reconstitution, the solution is drawn through the<br />sterile filter needle into a sterile disposable syringe. A<br />separate unused filter needle must be used to withdraw<br />each vial of reconstituted CEPROTIN. The solution<br />should be discarded if particulate matter is visible.<br />The reconstituted solution should be administered<br />immediately by intravenous injection.<br />CEPROTIN should be administered at a maximum<br />injection rate of 2 ml per minute. In children with a<br />body weight of less than 10 kg, the injection rate<br />should not exceed a rate of 0.2 ml/kg/min.<br />All unused solution, empty vials and used needles<br />and syringes must be discarded appropriately.<br />Frequency and duration of treatment depend on the<br />severity of your protein C deficiency, on the results of<br />determination of protein C levels in your plasma as<br />well as on the location and extent of thrombosis.<br />In case of acute thrombosis CEPROTIN may be<br />administered to you every 6 hours. As the tendency<br />for thrombus formation decreases, the frequency<br />may be reduced.<br />If you use more CEPROTIN than you should<br />It is recommended that you adhere to the dose level<br />and frequency of administration as recommended by<br />your doctor. In case you administered more<br />CEPROTIN than recommended, please inform your<br />doctor as soon as possible.<br />If you forget to use CEPROTIN<br />Not applicable.<br />If you stop using CEPROTIN<br />Do not stop using CEPROTIN without consulting<br />your doctor.<br />If you have any further questions on the use of this<br />medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side<br />effects, although not everybody gets them.<br />You may notice any of the following side effects after<br />administration of CEPROTIN:<br />&bull; As with any product administered by infusion into<br />a vein allergic reactions including severe and<br />potentially life-threatening reactions (anaphylaxis)<br />are possible.<br />You should be aware of the early signs of allergic<br />reactions such as burning and stinging at the<br />injection site, chills, flushing, rash, hives,<br />breathing difficulty, nausea, headache, lethargy,<br />low blood pressure, and tightness of the chest.<br />&bull; The following side effects were rarely observed<br />during clinical studies (less than 1 case in<br />1000 administrations given to patients): itching<br />(pruritus), rash and dizziness.<br />&bull; In the postmarketing experience there have been<br />reports of restlessness, excessive sweating, and<br />pain and redness at the injection site.<br />Reporting of side effects<br />If you get any side effects, talk to your doctor or<br />pharmacist. This includes any possible side effects<br />not listed in this leaflet. You can also report side<br />effects directly via the national reporting system listed<br />below. By reporting side effects you can help provide<br />more information on the safety of this medicine.<br />To report any side effect(s):<br />&bull; Saudi Arabia:<br />&ndash; The National Pharmacovigilance and Drug<br />Safety Centre (NPC)<br />&bull; Fax: +966-11-205-7662<br />&bull; Call NPC at +966-11-2038222,<br />Exts: 2317-2356-2353-2354-2334-2340.<br />&bull; Toll free phone: 8002490000<br />&bull; E-mail: npc.drug@sfda.gov.sa<br />&bull; Website: www.sfda.gov.sa/npc<br />&bull; Other GCC States:<br />&ndash; Please contact the relevant competent<br />authority.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of<br />children.<br />Do not use this medicine after the expiry date which<br />is stated on the label after EXP. The expiry date<br />refers to the last day of that month.<br />Store in a refrigerator (2&deg;C &ndash; 8&deg;C). Do not freeze.<br />Keep the vial in the outer carton in order to protect<br />from light.<br />The reconstituted solution should be used<br />immediately.<br />Do not throw away any medicines via wastewater or<br />household waste. Ask your pharmacist how to throw<br />away medicines you no longer use. These measures<br />will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>What CEPROTIN contains<br />Powder:<br />&ndash; The active substance is human protein C<br />&ndash; The other ingredients are human albumin, sodium<br />chloride and sodium citrate.2H2O. As solvent<br />Sterilised Water for Injections is used.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                CEPROTIN is presented as powder and solvent for
solution for injection and is a white or cream
coloured powder or friable solid. After reconstitution
the solution is colourless to slightly yellowish and
clear to slightly opalescent and essentially free from
visible particles.
Each pack also contains one transfer needle and
one filter needle.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>MAH:<br />BAXTER AG<br />Industriestrasse 72<br />A-1220 Vienna<br />Austria<br />Manufacturer:<br />BAXTER AG<br />Industriestrasse 67<br />A-1221 Vienna<br />Austria<br />For any information about this medicine, please<br />contact the local representative of the Marketing<br />Authorisation Holder.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last approved in Nov 2018
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>ينتمي سيبروتين إلى فئة من الأدوية يطلق عليها<br />اسم مضادات التخثر. يحتوي هذا الدواء على<br />&quot;بروتين سي&quot;، وهو بروتين طبيعي ينتجه الكبد<br />ويوجد في الدم. ويؤدي &quot;بروتين سي&quot; دورًا هامًا<br />في الوقاية من فرط تكون الجلطات، وبالتالي يمنع<br />و/أو يعالج التخثر داخل الأوردة.<br />يستخدم سيبروتين في علاج الجلطات والآفات<br />الجلدية النزفية )تسمى الفرفرية الخاطفة( والوقاية<br />منهما في المرضى الذين يعانون من نقص خلقي<br />شديد في بروتين &quot;سي&quot;.<br />إضافة إلى ما سبق، يمكن استخدام سيبروتين<br />لعلاج مضاعفات نادرة لأدوية ترقيق الدم )دواء<br />منع تخثر الدم ويسمى كُومارين( والتي يمكن أن<br />تسبب آفة جلدية خطيرة )نخر(.<br />فضلاً على ذلك، يستخدم سيبروتين لمنع تخثر الدم<br />في المرضى المصابين بنقص خلقي شديد في<br />بروتين &quot;سي&quot; وذلك في حالة استيفاء شرط أو<br />أكثر مما يلي:<br />&bull;قرب موعد الخضوع لجراحة أو علاج باضع<br />&bull;عند بدء العلاج بالكُومارين )دواء لمنع تخثر<br />الدم وترقيقه(<br />&bull;عندما يكون العلاج بالكُومارين وحده غير كافٍ<br />&bull;عندما يكون العلاج بالكُومارين غير ملائم.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>موانع استخدام سيبروتين،<br />&ndash; &ndash;إذا كانت لديك حساسية من بروتين سي<br />البشري أو المكونات الأخرى لهذا الدواء<br />)المذكورة في القسم 6( بما في ذلك البروتين<br />الفأري أو الهيبارين.<br />ورغم ذلك، في حالة حدوث مضاعفات خثارية-<br />مهددة للحياة، فربما يقرر الطبيب استمرار العلاج<br />بدواء سيبروتين.<br />تحذيرات واحتياطات<br />استشر طبيبك أو الصيدلاني قبل استخدام<br />سيبروتين. وتوخَ الحذر بشكل خاص عند استخدام<br />سيبروتين في حالة ظهور أعراض الحساسية.<br />وتتضمن أعراضها الطفح الجلدي والشرى<br />وصعوبات في التنفس وانخفاض ضغط الدم<br />وضيقاً بالصدر وصدمة. إذا حدثت مثل هذه<br />الأعراض خلال استخدام سيبروتين، فينبغي إيقاف<br />الحقن. قد تسبب هذه الأعراض رد فعل تحسسيًا<br />لأي من المكونات، أو تجاه البروتين الفأري أو<br />الهيبارين. ربما يحتوي المستحضر على آثار<br />الهيبارين و/أو البروتين الفأري نتيجة لعملية<br />التصنيع. إذا حدث مثل رد الفعل هذا، فسيقرر<br />طبيبك العلاج الأنسب.<br />إذا ﺗم ا ﺧﺗﺳدام ا ﺿﺣﺗﺳﻣﻟر ﻲﻓ ا ﻣﻟر ﻰﺿ اﻟذﯾن<br />ﻧﺎﻌﯾون ﻣن ﻘﻧص ﺷدﯾد ﻲﻓ ا ﺑﻟرو ﯾﺗن ﻰﺳ ا ﻲﻘﻠﺧﻟ ،<br />ﺈﻓن ا ﺎﺳﺟﻷم ا ﺎﺿﻣﻟدة ا ﺑﺛﻣﻟطﺔ ﻠﻟرو ﯾﺗن ﻰﺳ ﻗد<br />ﺗﺗطور و ﻛﻣﯾن أن ﺑﺛﺗط ا ﺑﻟرو ﯾﺗن ﻰﺳ و ﻲﻟﺎﺗﻟﺎﺑ ﻠﻘﺗل<br />ﻣن ﯾﺛﺄﺗر ا ﯾﺿﺣﺗﻟر. و ﻊﻣ ذﻟك ، ﻟم ﺣﻼﯾظ ھذا ﻲﻓ<br />اﻟدرا ﺎﺳت ا ﺳﻟرﯾر ﺔﯾ ﻰﺗﺣ اﻵن<br />عندما يتم تصنيع الأدوية من الدم أو البلازما<br />البشرية، يتم اتخاذ بعض الإجراءات لمنع انتقال<br />العدوى إلى المرضى. وتشمل هذه الإجراءات<br />انتقاء المتبرعين بالدم والبلازما بدقة للتأكد من<br />استبعاد الأشخاص الحاملين لخطر العدوى، ثم<br />اختبار كل تبرع وتجميعات البلازما بحثًا عن<br />وجود علامات فيروس/عدوى. كما تحرص<br />الشركات المصنعة لهذه المنتجات على إدراج<br />خطوات في عملية معالجة الدم أو البلازما تتيح<br />تعطيل نشاط الفيروسات أو التخلص منها. وعلى<br />الرغم من اتخاذ كل هذه التدابير، إلا أنه عند<br />استخدام الأدوية المُعدّة من الدم أو البلازما<br />البشرية، فلا يمكن استبعاد إمكانية انتقال العدوى<br />تمامًا. وهذا ينطبق أيضًا على أي فيروسات غير<br />معروفة أو مستجدة أو غيرها من أنواع العدوى.<br />تعتبر التدابير المتخذة فعّالة للبحث عن الفيروسات<br />المغلفة مثل فيروس نقص المناعة البشرية<br />HIV( ( وفيروس التهاب الكبد &quot;ب&quot; وفيروس<br />التهاب الكبد الوبائي &quot;سي&quot;، وفيروس التهاب<br />الكبد &quot;أ&quot;-غير المغلف. قد تكون التدابير المتخذة<br />ذات قيمة محدودة ضد الفيروسات-غير المغلفة<br />مثل الفيروسة الصغيرة &quot;ب 19 &quot;. قد تكون عدوى<br />الفيروسة الصغيرة &quot;ب 19 &quot; خطيرة للنساء<br />الحوامل )عدوى الجنين( وللأفراد الذين يعانون<br />من تثبيط بالجهاز المناعي أو من بعض أنواع فقر<br />الدم )مثل مرض الخلايا المنجلية أو فقر الدم<br />الانحلالي(.<br />قد يوصيك طبيبك بالتفكير في الحصول على<br />تطعيم ضد التهاب الكبد &quot;أ&quot; و&quot;ب&quot; إذا كنت<br />تتناول منتجات بروتين &quot;سي&quot;-المشتقة من<br />البلازما البشرية بصورة منتظمة/متكررة.<br />استخدام الأدوية الأخرى مع سيبروتين<br />لا توجد تفاعلات مع منتجات دوائية أخرى<br />معروفة حاليًا.<br />ومع ذلك، يرُجى إخبار الطبيب أو الصيدلاني في<br />حالة تناول أدوية أخرى مؤخرًا أو في الوقت<br />الحالي بما في ذلك الأدوية التي تصرف دون<br />وصفة طبية.<br />إذا قمت بالتغيير إلى العلاج بمضادات التخثر<br />الفموية، فيجب استمرار العلاج بتناول سيبروتين<br />إلى أن يكون مستوى الدم من مضادات تخثر الدم<br />الفموية كافيًا ومستقرًا.<br />تناول سيبروتين مع الطعام والشراب<br />لا تنطبق.<br />الحمل-والرضاعة الطبيعية<br />إذا كنتِ حاملً أو ترضعين رضاعة طبيعية أو<br />تعتقدين أنك ربما تكونين حاملً أو تخططين<br />للحمل، فاستشيري طبيبكِ أو الصيدلاني قبل تناول<br />هذا الدواء.<br />سوف يقرر طبيبك إذا كان يمكن استخدام<br />سيبروتين أثناء الحمل والرضاعة أم لا.<br />القيادة واستخدام الآلات<br />لا يؤثر سيبروتين على قدرتك على القيادة أو<br />تشغيل الآلات.<br />معلومات هامة عن بعض مكونات سيبروتين<br />بما أن كمية الصوديوم في الجرعة اليومية<br />القصوى قد تتجاوز 200 ملجم، فينبغي على<br />المرضى الذين يتبعون نظامًا غذائيًا محدود<br />الصوديوم. وضع ذلك في الاعتبار.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>سيبروتين مخصص للاستخدام عن طريق الوريد<br />)التسريب في الوريد(. ويتم إعطاؤه تحت إشراف<br />دقيق من طبيب ذي خبرة في العلاج البديل<br />لمثبطات/عوامل التخثر وفي مكان يتاح فيه رصد<br />نشاط البروتين &quot;سي&quot;. ستختلف الجرعة تبعًا<br />لحالتك ووزن الجسم.<br />الجرعة<br />تعتمد الجرعة وعدد مرات التناول ومدة العلاج<br />بناءً على شدة نقص البروتين &quot;سي&quot; لديك وعلى<br />حالتك السريرية ومستوى البلازما من البروتين<br />&quot;سي&quot;، وينبغي تعديل ما سبق وفقًا لذلك على<br />أساس الفعالية السريرية والتقييم المختبري.<br />وينبغي وصول نشاط البروتين &quot;سي&quot; إلى نسبة<br />100٪ في البداية، ثم الحفاظ على النشاط فوق<br />25٪ طول فترة العلاج.<br />يجب إعطاء جرعة أولية تتراوح ما بين 60 إلى<br />80 وحدة دولية/كجم. سيطلب الطبيب تحليل<br />صورة الدم عدة مرات مع مرور الوقت لتحديد<br />مدة احتفاظ جسمك ببروتين &quot;سي&quot;.<br />يوصى بقياس نشاط البروتين &quot;سي&quot; باستخدام<br />ركائز مولد اللون لتحديد مستوى البلازما<br />للبروتين &quot;سي&quot; قبل العلاج ب سيبروتين وأثناء<br />فترة العلاج.<br />يجب تحديد الجرعة على أساس القياسات<br />المختبرية لنشاط البروتين &quot;سي&quot;. أما في حالة<br />حدوث جلطة حادة فسيجب إجراء القياسات كل 6<br />ساعات حتى تستقر حالتك، وبعد ذلك مرتين يوميًا<br />ودائمًا قبل الحقنة التالية مباشرة. ينبغي تذكر أن<br />عمر النصف-للبروتين &quot;سي&quot; ربما تقل بدرجة<br />كبيرة في بعض الحالات السريرية مثل تخثر الدم<br />الحاد المصحوب بالفرفرية الخاطفة ونخر الجلد.<br />إذا كنت مصاباً بمرض في الكلى و/أو الكبد،<br />فيرجى إبلاغ الطبيب، لأنه قد يضطر إلى تعديل<br />العلاج وفقاً لذلك.<br />إذا تحوّلت إلى العلاج الوقائي الدائم باستخدام<br />مضادات التخثر الفموية، فسيلزم إيقاف بديل<br />البروتين &quot;سي&quot; فقط عند استقرار تخثر الدم<br />)انظر &quot;معلومات هامة عن بعض مكونات<br />سيبروتين&quot;(.<br />إذا تلقيت علاجًا وقائيًا يحتوي على البروتين<br />&quot;سي&quot;، فقد يكون ارتفاع مستويات أقل تركيز<br />للدواء مُبررًا في حالات تزايد خطر تجلط الدم<br />)مثل العدوى، والرضوض، أو التدخل الجراحي(.<br />إذا كنت مصاباً بمقاومة البروتين &quot;سي&quot; المُنشّط<br />والذي يمثل عامل خطورة للانصمام الخثاري<br />يصيب ما يصل إلى ٪ 5 من سكان أوروبا فربما<br />يحتاج الطبيب إلى ضبط العلاج وفقًا لذلك.<br />التناول<br />سيتم إعطاؤك سيبروتين عن طريق الحقن في<br />الوريد بعد إعادة إذابة مسحوق الحقن بالماء<br />المعقم المخصص للحقن. ويوصى بشدة بتسجيل<br />اسم المنتج ورقم الدفعة في كل مرة تتلقى فيها<br />جرعة من سيبروتين للحفاظ على سجل بالدفعات<br />المستخدمة.<br />أذِب مسحوق سيبروتين باستخدام المذيب المرفق<br />)ماء معقم للحقن( مستخدمًا إبرة النقل المعقمة. ثم<br />لف القنينة بلطف حتى يذوب المسحوق بالكامل.<br />بعد إعادة الإذابة، اسحب المحلول بإبرة الفلتر<br />المعقمة إلى حقنة معقمة معدّة للاستعمال لمرة<br />واحدة. يجب استخدام إبرة فلتر مستقلة غير<br />مستخدمة مسبقًا لسحب سيبروتين المذاب من كل<br />قنينة. يجب التخلص من المحلول إذا كانت<br />الجسيمات مرئية.<br />يجب إعطاء المحلول فورًا عن طريق الحقن<br />الوريدي.<br />وينبغي تناول سيبروتين بمعدل حقن 2 مل في<br />الدقيقة كحد أقصى. وبالنسبة للأطفال الذين يقل<br />وزن جسمهم عن 10 كجم، فيجب أن لا يتجاوز<br />معدل الحقن 0.2 مل/كجم/دقيقة.<br />يجب التخلص من جميع المحاليل غير المستخدمة<br />والقنينات الفارغة والإبر والمحاقن المستخدمة<br />بشكل مناسب.<br />يعتمد عدد مرات التناول ومدة العلاج على شدة<br />نقص البروتين &quot;سي&quot;، وبناءً على نتائج تحديد<br />مستويات البروتين &quot;سي&quot; في البلازما وكذلك<br />موقع تجلط الدم ودرجته.<br />في حالة تجلط الدم الحاد يمكن استخدام سيبروتين<br />كل 6 ساعات. ومع تراجع الاستعداد نحو تكوّن<br />الجلطات الدموية، يمكن تقليل عدد مرات التناول.<br />في حالة استخدام جرعة أكبر مما ينبغي من<br />سيبروتين<br />ننصح بالالتزام بمستوى الجرعة وعدد مرات<br />تناول الدواء على النحو الذي أوصى به الطبيب.<br />في حال تناولك جرعة سيبروتين أكبر من<br />الموصى بها، فيرجى إبلاغ الطبيب في أسرع<br />وقت ممكن.<br />إذا نسيت تناول سيبروتين<br />لا تنطبق.<br />إذا توقفت عن تناول سيبروتين<br />لا تتوقف عن استخدام سيبروتين دون استشارة<br />طبيبك.<br />إذا كانت لديك أي أسئلة إضافية حول استخدام هذا<br />الدواء، فاسأل طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>يمكن أن يتسبب هذا الدواء مثل جميع الأدوية في<br />حدوث آثار جانبية، على الرغم من عدم تعرض<br />جميع المرضى لها.<br />قد تلاحظ أيًا من الآثار الجانبية التالية بعد تناول<br />سيبروتين:<br />&bull; ﺎﻤﻛ &nbsp;ﻮﻫ ا ﺎﺤﻟل ﻊﻣ أي ﺞﺘﻨﻣ ﻢﺘﻳ ا ﺪﺨﺘﺳا ﻪﻣ ﻦﻋ<br />ط ﻖﻳﺮ ا ﺐﻳﺮﺴﺘﻟ ﻲﻓ ا ﻮﻟر ﺪﻳ، ر ﺎﻤﺑ ﺪﺤﺗث ردود<br />ﻞﻌﻓ ﺔﻴﺴﺴﺤﺗ، ﺎﻤﺑ ﻲﻓ ذ ﻚﻟ ردود ا ﻞﻌﻔﻟ ا ﺎﺤﻟدة<br />وا ﻞﻤﺘﺤﻤﻟ أن ﻮﻜﺗن ﺪﻬﻣدة- ﺎﻴﺤﻠﻟة )العوار(<br />&bull; ﺐﺠﻳ &nbsp;ﺔﻓﺮﻌﻣ ا ﺎﻣﻼﻌﻟت ا ﺮﻜﺒﻤﻟة ﻰﻠﻋ ردود ا ﻞﻌﻔﻟ<br />ا ﺔﻴﺴﺴﺤﺘﻟ ﻞﺜﻣ ا ﺎﻗﺮﺤﻟن وا ﺰﺧﻮﻟ ﻲﻓ ﻊﻗﻮﻣ ا ﻦﻘﺤﻟ<br />و ﺮﻳﺮﻌﺸﻗة وا ﺮﻤﺣار وط ﺢﻔ ﺪﻠﺟي و ﺮﺷى<br />و ﺔﺑﻮﻌﺻ ا ﻔﻨﺘﻟس و ﺎﻴﺜﻏن و ﺪﺻاع و ﻮﻤﺧل<br />وا ﺎﻔﺨﻧض ﻂﻐﺿ ا ﺪﻟم و ﻖﻴﺿ ﺪﺼﻟﺎﺑر.<br />&bull;نادرًا ما لوحظت الآثار الجانبية التالية خلال<br />الدراسات السريرية )أقل من حالة واحدة في<br />1000 حالة لمرضى تم إعطاؤهم الدواء(:<br />الحكة )الحُكَاك(، والطفح الجلدي والدوخة.<br />&bull;في تجربة ما بعد التسويق كشفت التقارير عن<br />وجود أرق وفرط التعرق وألم واحمرار في<br />موقع الحقن<br />الإبلاغ عن الآثار الجانبية<br />إذا أُصبت بأي آثار جانبية، فتحدث مع طبيبك أو<br />الصيدلي. يشمل هذا أي آثار جانبية محتملة غير<br />مدرجة في هذه النشرة. يمكنك أيضًا الإبلاغ عن<br />الآثار الجانبية مباشرة عن طريق نظام الإبلاغ<br />الوطني المذكور أدناه. بإبلاغك عن الآثار<br />الجانبية، يمكنك المساعدة في توفير المزيد من<br />المعلومات حول سلامة هذا الدواء.<br />للإبلاغ عن أي آثار جانبية:<br />&bull;المملكة العربية السعودية:<br />&ndash; &ndash;المركز الوطني للتيقظ والسلامة الدوائية<br />&bull;فاكس: 7662 - 205 - 11 - 966 +<br />&bull; اتصل بالمركز الوطني للتيقظ والسلامة الدوائية<br />على رقم + 2038222 - 11 - 966 ، الرقم<br />الداخلي:<br />.2317-2356-2353-2354-2334-2340&bull;<br />&bull;الهاتف المجاني: 8002490000<br />&bull;البريد الإلكتروني:<br />npc.drug@sfda.gov.sa<br />&bull;الموقع الإلكتروني: www.sfda.gov.sa/npc<br />&bull;دول مجلس التعاون الخليجي الأخرى:<br />يرجى الاتصال بالسلطة المختصة ذات الصلة</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>احفظ هذا الدواء بعيدًا عن متناول ومرأى<br />الأطفال.<br />لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية<br />المذكور على الملصق بعد كلمة EXP . يشير<br />تاريخ انتهاء الصلاحية إلى آخر يوم من الشهر<br />المذكور.<br />يحفظ في الثلاجة في درجة حرارة )&deg; 2 &ndash; &deg; 8<br />درجات مئوية(. لا يُجمّد.<br />احفظ القنينة في العبوة الخارجية لحمايتها من<br />الضوء.<br />يجب استخدام المحلول المذاب فورًا.<br />لا تتخلص من أي أدوية عبر مياه الصرف<br />الصحي أو المخلفات المنزلية. اسأل الصيدلي<br />الذي تتعامل معه عن طريقة التخلص من<br />الأدوية التي لم تعد تستخدمها. ستساعد هذه<br />التدابير على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>محتويات سيبروتين<br />مسحوق:<br />&ndash; &ndash;المادة الفعّالة هي بروتين &quot;سي&quot; البشري<br />&ndash; &ndash;المكونات الأخرى هي ألبيومين بشري<br />وكلوريد الصوديوم و ملح الصوديوم الثلاثي<br />لحمض الستريك. كما تستخدم المياه المعقمة<br />المخصصة للحقن كمذيب.<br />شكل سيبروتين ومحتويات العبوة<br />يأتي سيبروتين في صورة مسحوق مع مُذيب لعمل<br />محلول الحقن ويكون مسحوقًا أو مادة صلبة سهلة<br />التفتت باللون الأبيض أو الكريمي. بعد الإذابة،<br />يكون المحلول عديم اللون إلى مصفر قليلاً ورائقًا<br />إلى غائم قليلاً وخاليًا تمامًا من الجسيمات المرئية<br />بشكل أساسي.<br />تحتوي كل عبوة أيضًا على إبرة نقل واحدة وإبرة<br />فلتر واحدة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>-----</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>حامل ترخيص التسويق والشركة المصنعة<br />الشركة المسوّقة:<br />باكستر إيه جي، 1220 فيينا، النمسا<br />الشركة الصانعة:<br />باكستر إيه جي، 1221 فيينا، النمسا<br />للحصول على أي معلومات حول هذا الدواء،<br />يرجى الاتصال بالممثل المحلي لحامل ترخيص<br />التسويق:</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
             نوفمبر 2018
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                CEPROTIN 500 IU powder and solvent for solution for injection
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Protein C from human plasma purified by mouse monoclonal antibodies. CEPROTIN 500 IU* is prepared as a powder containing nominally 500 IU human protein C per container. The product reconstituted with 5 ml of Sterilised Water for Injections contains approximately 100 IU/ml human protein C.
The potency (IU) is determined using a chromogenic substrate method against the World Health Organisation (WHO) International standard.
Excipients with known effect:
Sodium chloride: 44 mg/vial Sodium citrate. 2H2O: 22 mg/vial
For the full list of excipients see section 6.1.
* One International Unit (IU) of protein C corresponds to the amidolytically measured activity of protein C in 1 ml of normal plasma.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Powder and solvent for solution for injection.
White or cream coloured powder or friable solid. After reconstitution the solution has a pH of between 6.7 and 7.3 and an osmolality of not lower than 240 mosmol/kg.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>CEPROTIN is indicated in purpura fulminans and coumarin-induced skin necrosis in patients with severe congenital protein C deficiency. Furthermore CEPROTIN is indicated for short-term prophylaxis in patients with severe congenital protein C deficiency if one or more of the following conditions are met:<br />&bull; surgery or invasive therapy is imminent<br />&bull; while initiating coumarin therapy<br />&bull; when coumarin therapy alone is not sufficient<br />&bull; when coumarin therapy is not feasible.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment with CEPROTIN should be initiated under the supervision of a physician experienced in substitution therapy with coagulation factors/inhibitors where monitoring of protein C activity is feasible.<br />The dose should be adjusted on the basis of laboratory assessment for each individual case.<br />A protein C activity of 100 % should be achieved initially and the activity should be maintained above 25 % for the duration of the treatment.<br />3<br />An initial dose of 60 to 80 IU/kg for determination of recovery and half-life is advised.<br />The measurement of protein C activity using chromogenic substrates is recommended for the determination of the patient&rsquo;s plasma level for protein C before and during treatment with CEPROTIN.<br />The dosage should be determined on the basis of laboratory measurements of the protein C activity. In the case of an acute thrombotic event these should be performed every 6 hours until the patient is stabilised, thereafter twice a day and always immediately before the next injection. It should be kept in mind that the half-life of protein C may be severely shortened in certain clinical conditions such as acute thrombosis with purpura fulminans and skin necrosis.<br />Patients treated during the acute phase of their disease may display much lower increases in protein C activity. The wide variation in individual responses implies that the effects of CEPROTIN on coagulation parameters should be checked regularly.<br />Patients with renal and/or hepatic impairment should be monitored more closely. (see section 4.4)<br />Based on the limited clinical experience in children from reports and studies covering 83 patients, dosing guidelines for adult subjects are considered valid for neonatal and paediatric patient population (see section 5.1).<br />In rare and exceptional cases, subcutaneous infusion of 250-350 IU/kg was able to produce therapeutic protein C plasma levels in patients with no intravenous access.<br />If the patient is switched to permanent prophylaxis with oral anticoagulants, protein C replacement is to be discontinued only when stable anticoagulation is obtained (see section 4.5). Furthermore, during the initiation of oral anticoagulant therapy it is advisable to start with a low dose and adjust this incrementally, rather than use a standard loading dose.<br />In patients receiving prophylactic administration of protein C, higher trough levels may be warranted in situations of an increased risk of thrombosis (such as infection, trauma, or surgical intervention).<br />In patients with combined severe congenital protein C deficiency and with APC resistance, there are limited clinical data to support the safety and efficacy of CEPROTIN.<br />CEPROTIN is administered by intravenous injection after reconstitution of the powder for solution for injection with Sterilised Water for Injections.<br />CEPROTIN should be administered at a maximum injection rate of 2 ml per minute except for children with a body weight of &lt; 10 kg, where the injection rate should not exceed a rate<br />of 0.2 ml/kg/min.<br />As with any intravenous protein product, allergic type hypersensitivity reactions are possible. For the events that allergic symptoms arise which are of an acute and life-threatening nature, administration should be made within reach of life-supporting facilities.<br />For instructions on reconstitution of the medicinal product before administration, see section.6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Treatment with CEPROTIN should be initiated under the supervision of a physician experienced in substitution therapy with coagulation factors/inhibitors where monitoring of protein C activity is feasible.
The dose should be adjusted on the basis of laboratory assessment for each individual case.
A protein C activity of 100 % should be achieved initially and the activity should be maintained above 25 % for the duration of the treatment.
3
An initial dose of 60 to 80 IU/kg for determination of recovery and half-life is advised.
The measurement of protein C activity using chromogenic substrates is recommended for the determination of the patient’s plasma level for protein C before and during treatment with CEPROTIN.
The dosage should be determined on the basis of laboratory measurements of the protein C activity. In the case of an acute thrombotic event these should be performed every 6 hours until the patient is stabilised, thereafter twice a day and always immediately before the next injection. It should be kept in mind that the half-life of protein C may be severely shortened in certain clinical conditions such as acute thrombosis with purpura fulminans and skin necrosis.
Patients treated during the acute phase of their disease may display much lower increases in protein C activity. The wide variation in individual responses implies that the effects of CEPROTIN on coagulation parameters should be checked regularly.
Patients with renal and/or hepatic impairment should be monitored more closely. (see section 4.4)
Based on the limited clinical experience in children from reports and studies covering 83 patients, dosing guidelines for adult subjects are considered valid for neonatal and paediatric patient population (see section 5.1).
In rare and exceptional cases, subcutaneous infusion of 250-350 IU/kg was able to produce therapeutic protein C plasma levels in patients with no intravenous access.
If the patient is switched to permanent prophylaxis with oral anticoagulants, protein C replacement is to be discontinued only when stable anticoagulation is obtained (see section 4.5). Furthermore, during the initiation of oral anticoagulant therapy it is advisable to start with a low dose and adjust this incrementally, rather than use a standard loading dose.
In patients receiving prophylactic administration of protein C, higher trough levels may be warranted in situations of an increased risk of thrombosis (such as infection, trauma, or surgical intervention).
In patients with combined severe congenital protein C deficiency and with APC resistance, there are limited clinical data to support the safety and efficacy of CEPROTIN.
CEPROTIN is administered by intravenous injection after reconstitution of the powder for solution for injection with Sterilised Water for Injections.
CEPROTIN should be administered at a maximum injection rate of 2 ml per minute except for children with a body weight of < 10 kg, where the injection rate should not exceed a rate
of 0.2 ml/kg/min.
As with any intravenous protein product, allergic type hypersensitivity reactions are possible. For the events that allergic symptoms arise which are of an acute and life-threatening nature, administration should be made within reach of life-supporting facilities.
For instructions on reconstitution of the medicinal product before administration, see section.6.6.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>As the risk of an allergic type hypersensitivity reaction cannot be excluded, patients should be informed of the early signs of hypersensitivity reactions including hives, generalized urticaria, tightness of the chest, wheezing, hypotension, and anaphylaxis. If these symptoms occur, they should inform the physician. Immediate discontinuation of product use is advised.<br />In case of shock, the current medical standards for shock treatment are to be observed.<br />No experience in the treatment of patients with renal and/or hepatic impairment is available and therefore it is recommended that such patients be monitored more closely.<br />If the preparation is used in patients with severe congenital protein C deficiency, antibodies inhibiting protein C may develop.<br />Standard measures to prevent infections resulting from the use of medicinal products prepared from human blood or plasma include selection of donors, screening of individual donations and plasma pools for specific markers of infection, and the inclusion of effective manufacturing steps for the inactivation/removal of viruses. Despite this, when medicinal products prepared from human blood or plasma are administered, the possibility of transmitting infective agents cannot be totally excluded.<br />This also applies to unknown or emerging viruses and other pathogens.<br />The measures taken are considered effective for enveloped viruses such as HIV, HBV and HCV and for the non-enveloped virus HAV. The measures taken may be of limited value against non-enveloped viruses such as parvovirus B19. Parvovirus B19 infection may be serious for pregnant women (fetal infection) and for individuals with immunodeficiency or increased erythropoiesis (e.g. haemolytic anaemia).<br />Appropriate vaccination (hepatitis A and B) should be considered for patients in regular / repeated receipt of human plasma-derived Protein C products.<br />It is strongly recommended that every time that CEPROTIN is administered to a patient, the name and batch number of the product are recorded in order to maintain a link between the patient and the batch of the product.<br />CEPROTIN may contain trace amounts of heparin. Heparin induced allergic reactions, which can be associated with a rapid decrease of the number of thrombocytes, may be observed (heparin induced thrombocytopenia [HIT]). In patients with HIT, symptoms such as arterial and venous thrombosis, disseminated intravascular coagulation (DIC), purpura, petechiae and gastrointestinal bleeding (melena), may occur. If HIT is suspected, the number of thrombocytes should be determined immediately and if necessary therapy with CEPROTIN should be stopped. Identifying HIT is complicated by the fact that these symptoms may already be present in acute phase patients with severe congenital protein C deficiency. Patients with HIT should avoid the use of heparin containing drugs in the future.<br />In the context of clinical experience several bleeding episodes have been observed. Concurrent anticoagulant medication (such as heparin) may have been responsible for these bleeding episodes. However, it cannot be completely ruled out that the administration of CEPROTIN further contributed to these bleeding events.<br />The quantity of sodium in the maximum daily dose may exceed 200 mg. This should be taken into consideration by patients on a controlled sodium diet.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No interactions with other medicinal products are currently known.<br />In patients starting treatment with oral anticoagulants belonging to the class of vitamin K antagonists (e.g. warfarin), a transient hypercoagulable state may arise before the desired anticoagulant effect becomes apparent. This transient effect may be explained by the fact that protein C, itself a vitamin K dependent plasma protein, has a shorter half-life than most of the vitamin K dependent proteins<br />(i.e. II, IX and X). Subsequently, in the initial phase of treatment, the activity of protein C is more rapidly suppressed than that of the procoagulant factors. For this reason, if the patient is switched to oral anticoagulants, protein C replacement must be continued until stable anticoagulation is obtained. Although Warfarin-induced skin necrosis can occur in any patient during the initiation of oral anticoagulant therapy, individuals with congenital protein C deficiency are particularly at risk.<br />(See section 4.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Although CEPROTIN has been used safely in the treatment of pregnant protein C-deficient women,<br />its safety for use in human pregnancy has not been established in controlled clinical trials. Furthermore no information on excretion of protein C in the milk is available. Therefore, the benefit of using CEPROTIN during pregnancy or lactation must be judged against the risk for the mother and baby, and should be used only if clearly needed.<br />See section 4.4 for information on parvovirus B19 infection.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>CEPROTIN has no influence on the ability to drive and use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>As with any intravenous product allergic type hypersensitivity reactions are possible. Patients should be informed of the early signs of hypersensitivity reactions, which may include angioedema, burning and stinging at the injection site, chills, flushing, rash, pruritus, generalised urticaria, headache, hives, hypotension, lethargy, nausea, restlessness, tachycardia, tightness of the chest, tingling, vomiting, and wheezing. Patients should be advised to immediately contact their physician if these symptoms occur (see section 4.4).<br />During clinical studies with CEPROTIN, a total of adverse drug reactions (ADRs) were reported in 1 of 67 patients enrolled (rash and pruritus (grouped as hypersensitivity), and dizziness). In total 6375 administrations of CEPROTIN have been given. The distribution of the related ADRs is as follows:<br />The following ADRs have been reported in the post-marketing experience:<br />Psychiatric disorders restlessness<br />Skin and subcutanesous tissue disorders hyperhydrosis<br />General disorders and administration site conditions injection site reaction<br />The frequency of these ADRs is not known.<br />Reporting of suspected adverse reactions<br />Reporting suspected adverse reactions after authorisation of the medicinal product is important.<br />It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system.<br />To report any side effect(s):<br />&bull; Saudi Arabia:<br />□ Other GCC States:<br />- The National Pharmacovigilance and Drug Safety Centre (NPC)<br />□ Fax: +966-11-205-7662<br />□ Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.<br />□ Toll free phone: 8002490000<br />□ E-mail: npc.drug@sfda.gov.sa<br />□ Website: www.sfda.gov.sa/npc<br />Other GCC States:<br />- Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No symptoms of overdose with CEPROTIN have been reported.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: group antithrombotic; ATC Code: B01AD12<br />Protein C is a vitamin K-dependent anticoagulant glycoprotein which is synthesised in the liver. It is converted by thrombin/thrombomodulin-complex on the endothelial surface to activated protein C (APC). APC is a serine protease with potent anticoagulant effects, especially in the presence of its cofactor protein S. APC exerts its effect by the inactivation of the activated forms of factors V and VIII which leads to a decrease in thrombin formation. APC has also been shown to have profibrinolytic effects.<br />The intravenous administration of CEPROTIN provides for an immediate but temporary increase in plasma levels of protein C. Replacement of protein C in protein C deficient patients is expected to control or - if given prophylactically - prevent thrombotic complications.<br />Twelve courses of short-term prophylaxis prior to surgery or invasive therapy and 7 courses of long-term prophylaxis were included in the efficacy analyses.<br />No formal clinical study in either paediatric or neonatal population with severe congenital protein C deficiency was ever conducted. However, several small retrospective and prospective studies investigating other clinical application areas have been published in this population. Indication was prevention and treatment of purpura fulminans and thrombotic disease, enrolling overall 14 subjects of 2 days old throughout adolescence.<br />Other experience with CEPROTIN covers case reports and a clinical study in overall 69 paediatric patients with acquired protein C deficiency. The study is a randomized, double-blind,<br />placebo-controlled dose-finding study, in the indication of acquired protein C deficiency due to meningococcal sepsis (IMAG 112). The reports suggest that CEPROTIN is well tolerated in children and small infants.<br />Dosages of the above studies, covering 83 patients, indicate that dosing guidelines for adult subjects are also valid for neonatal and paediatric patient population.<br />In rare and exceptional cases, subcutaneous infusion of 250-350 IU/kg was able to produce therapeutic protein C plasma levels in patients with no intravenous access.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>21 asymptomatic subjects with homozygous or double heterozygous protein C deficiency were evaluated for pharmacokinetic data. The protein C plasma activity was measured by chromogenic assay. The individual half-lives varied from 4.4 to 15.8 hours using a compartmental model and from 4.9 to 14.7 using the non-compartmental method. The individual incremental recovery ranged from 0.50 to 1.76 [(IU/dL)/(IU/kg)]. The patients differed significantly in age, body weight and plasma volume.<br />In patients with acute thrombotic disease, both the incremental increase in protein C plasma levels as well as half-life may be considerably reduced.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Protein C contained in CEPROTIN is a normal constituent of human plasma and acts like endogenous protein C. Therefore experimental studies on tumorigenic or mutagenic effects - particularly in heterologous species - are not considered necessary.<br />Single dose toxicity testing showed that even doses of several times the recommended human dosage per kilogram body weight (10-fold) did not result in toxic effects on rodents.<br />CEPROTIN proved to have no mutagenic potential in the Ames test performed.<br />Repeated toxicity studies were not conducted because prior experience with coagulation preparations had shown them to be of limited value. Difference between the recipient species and human Protein C will inevitably result in an immune response with antibody formation.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Powder<br />Human albumin Sodium chloride Sodium citrate. 2H20<br />Solvent<br />Sterilised Water for Injections</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years
The reconstituted solution should be used immediately.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in a refrigerator (2C &ndash; 8C). Do not freeze. Keep the vial in the outer carton in order to protect from light.<br />For storage conditions after reconstitution of the medicinal product, see section 6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>500 IU and 1000 IU: CEPROTIN powder comes in vials of neutral glass of either hydrolytic type I (500 IU) or hydrolytic type II (1000 IU). The solvent comes in vials of neutral glass of hydrolytic type I. The product and the solvent vials are closed with butyl rubber stoppers.<br />Each pack also contains:<br />&bull; one transfer needle<br />&bull; one filter needle<br />Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Reconstitute lyophilised CEPROTIN powder for solution for injection, with the supplied solvent (Sterilised Water for Injections) using the sterile transfer needle. Gently rotate the vial until all powder is dissolved. After reconstitution the solution is colourless to slightly yellowish and clear to slightly opalescent and essentially free from visible particles.<br />The solution is drawn through the sterile filter needle into a sterile disposable syringe. A separate unused filter needle must be used to withdraw each vial of reconstituted CEPROTIN. The solution should be discarded if particulate matter is visible.<br />The reconstituted solution should be administered immediately by intravenous injection.<br />Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                BAXTER AG
Industriestrasse 67 A-1220 Vienna Austria
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                21-11-2018
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>